Analysis of the Empyema without Pus (Organized Empyema)

A Novel Approach to Life-Threatening Cardiorespiratory Distress from Mediastinum Exclusion Type Chronic Empyema

“…Iuchi et al stated that empyema should be surgically treated at the earliest possible stage prior to the development of infection. 1 In such cases, surgical invasion should be minimized as much as possible, since the preoperative condition is typically extremely poor.…”

“…Among them is matrical empyema, a mediastinal exclusion type of empyema (MEE) that shows no retention of pus in the thoracic cavity, though it is clinically included as a type of empyema. 1 In this condition, the thoracic cavity is filled with necrotic substances and solid matter that gradually increases in volume without infection. The number of patients with this condition who undergo treatment is limited since they tend to be rarely correctly diagnosed, because the progress of symptoms is gradual and there is no associated infection.…”

“…Accordingly, most cases are left untreated. [1][2][3] We experienced four cases of MEE on the left side accompanied with cardiorespiratory insufficiency, for which medical treatment became difficult, and we treated them with surgery as a semiemergency. The patients required safe and effective treatment, with an extirpation of the empyemic thoracic cavity and a panpleuropneumonectomy due to their unfavorable condition.…”

Rupture of a chronic expanding hematoma of the thorax into lung parenchyma

“…Pier Luigi Filosso, MD, a Anna Arslanian, MD, a Nicola Palestini, MD, b Alessandra Farnetti, MD, b Mauro Papotti, MD, c Massimo Bongiovanni, MD, c Roberto Giobbe, MD, a and Enrico Ruffini, MD, a Torino, Italy B ronchial carcinoids (BCs) are rare and constitute less than 2% of pulmonary tumors. 1 They are characterized by slow, mainly endobronchial growth, with infrequent regional lymph node involvement or distant metastases. 2 Atypical carcinoids are part of the spectrum of neuroendocrine bronchopulmonary tumors, according to the 1999 World Health Organization-International Association for the Study of Lung Cancer (WHO-IASLC) Lung Tumor classification.…”